Current and historical daily PE Ratio for FBLG (
FibroBiologics Inc
) from 2024 to May 24 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. FibroBiologics stock (FBLG) PE ratio as of May 24 2024 is 0.
More Details
FibroBiologics Inc (FBLG) PE Ratio (TTM) Chart
FibroBiologics Inc (FBLG) PE Ratio (TTM) Historical Data
View and export this data going back to 2024. Start your Free Trial
Total 81
- 1
| FibroBiologics PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-05-24 | At Loss | 2024-03-28 | At Loss |
| 2024-05-23 | At Loss | 2024-03-27 | At Loss |
| 2024-05-22 | At Loss | 2024-03-26 | At Loss |
| 2024-05-21 | At Loss | 2024-03-25 | At Loss |
| 2024-05-20 | At Loss | 2024-03-22 | At Loss |
| 2024-05-17 | At Loss | 2024-03-21 | At Loss |
| 2024-05-16 | At Loss | 2024-03-20 | At Loss |
| 2024-05-15 | At Loss | 2024-03-19 | At Loss |
| 2024-05-14 | At Loss | 2024-03-18 | At Loss |
| 2024-05-13 | At Loss | 2024-03-15 | At Loss |
| 2024-05-10 | At Loss | 2024-03-14 | At Loss |
| 2024-05-09 | At Loss | 2024-03-13 | At Loss |
| 2024-05-08 | At Loss | 2024-03-12 | At Loss |
| 2024-05-07 | At Loss | 2024-03-11 | At Loss |
| 2024-05-06 | At Loss | 2024-03-08 | At Loss |
| 2024-05-03 | At Loss | 2024-03-07 | At Loss |
| 2024-05-02 | At Loss | 2024-03-06 | At Loss |
| 2024-05-01 | At Loss | 2024-03-05 | At Loss |
| 2024-04-30 | At Loss | 2024-03-04 | At Loss |
| 2024-04-29 | At Loss | 2024-03-01 | At Loss |
| 2024-04-26 | At Loss | 2024-02-29 | At Loss |
| 2024-04-25 | At Loss | 2024-02-28 | At Loss |
| 2024-04-24 | At Loss | 2024-02-27 | At Loss |
| 2024-04-23 | At Loss | 2024-02-26 | At Loss |
| 2024-04-22 | At Loss | 2024-02-23 | At Loss |
| 2024-04-19 | At Loss | 2024-02-22 | At Loss |
| 2024-04-18 | At Loss | 2024-02-21 | At Loss |
| 2024-04-17 | At Loss | 2024-02-20 | At Loss |
| 2024-04-16 | At Loss | 2024-02-16 | At Loss |
| 2024-04-15 | At Loss | 2024-02-15 | At Loss |
| 2024-04-12 | At Loss | 2024-02-14 | At Loss |
| 2024-04-11 | At Loss | 2024-02-13 | At Loss |
| 2024-04-10 | At Loss | 2024-02-12 | At Loss |
| 2024-04-09 | At Loss | 2024-02-09 | At Loss |
| 2024-04-08 | At Loss | 2024-02-08 | At Loss |
| 2024-04-05 | At Loss | 2024-02-07 | At Loss |
| 2024-04-04 | At Loss | 2024-02-06 | At Loss |
| 2024-04-03 | At Loss | 2024-02-05 | At Loss |
| 2024-04-02 | At Loss | 2024-02-02 | At Loss |
| 2024-04-01 | At Loss | 2024-02-01 | At Loss |
FibroBiologics Inc (FBLG) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
FibroBiologics Inc
NAICS : 541713
SIC : 2833
ISIN : US31573L1052
Description
FibroBiologics Inc is a clinical-stage cell therapy company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including degenerative disc disease, multiple sclerosis, wound healing, and certain cancers, and potential extension of life applications including thymic and splenic involution reversal.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers